Priya Singhal Sells 2,660 Shares of Biogen (NASDAQ:BIIB) Stock

Biogen Inc. (NASDAQ:BIIB) insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Priya Singhal also recently made the following trade(s):

• On Monday, February 2nd, Priya Singhal sold 748 shares of Biogen stock. The stock was sold at an average price of $179.30, for a total transaction of $134,116.40.

Biogen Stock Performance

NASDAQ:BIIB opened at $191.20 on Thursday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. Biogen Inc. has a 52-week low of $110.04 and a 52-week high of $202.41. The firm has a market capitalization of $28.06 billion, a PE ratio of 21.70, a P/E/G ratio of 1.50 and a beta of 0.16. The stock has a 50-day simple moving average of $177.65 and a two-hundred day simple moving average of $158.12.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.38. The company had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter last year, the company earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts forecast that Biogen Inc. will post 15.83 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BIIB. Mizuho lifted their price objective on Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research report on Tuesday. Stifel Nicolaus raised their price target on Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Canaccord Genuity Group upped their price target on Biogen from $220.00 to $230.00 and gave the company a “buy” rating in a report on Monday. BMO Capital Markets lifted their price target on Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research report on Friday, February 6th. Finally, TD Cowen lifted their target price on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday. Thirteen investment analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. According to data from MarketBeat.com, Biogen presently has an average rating of “Hold” and an average target price of $206.54.

Institutional Investors Weigh In On Biogen

Institutional investors and hedge funds have recently modified their holdings of the stock. Empowered Funds LLC increased its position in shares of Biogen by 64.9% in the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after purchasing an additional 2,777 shares during the last quarter. Focus Partners Wealth boosted its stake in Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after purchasing an additional 6,436 shares during the period. Sivia Capital Partners LLC bought a new position in Biogen in the 2nd quarter worth approximately $216,000. Blair William & Co. IL increased its holdings in shares of Biogen by 11.8% during the second quarter. Blair William & Co. IL now owns 14,844 shares of the biotechnology company’s stock valued at $1,864,000 after purchasing an additional 1,561 shares during the period. Finally, Callan Family Office LLC bought a new stake in Biogen during the second quarter worth approximately $308,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat FY‑2026 guidance — Biogen reported Q4 results that topped EPS and revenue expectations and provided FY‑2026 EPS guidance (15.25–16.25) that reassured investors about earnings power. This is a primary driver of recent price strength. Why Biogen Is Up After Earnings
• Positive Sentiment: Analyst upgrades and higher price targets — Several firms raised targets and reiterated buys after the results (examples: Mizuho, Goldman Sachs, Canaccord, Citigroup and others), supporting further upside sentiment. Mizuho Raises Price Target
• Positive Sentiment: Regulatory progress for Leqembi (lecanemab) — The BLA for a subcutaneous formulation of Leqembi received priority review, which could expand commercial reach and margins if approved. That helped sentiment around Biogen’s Alzheimer’s growth runway. Leqembi Subcutaneous Priority Review
• Neutral Sentiment: Board leadership change — Caroline Dorsa is retiring as Board Chair; Dr. Maria C. Freire was elected Chair effective immediately. Governance continuity reduces uncertainty but is unlikely to be a major near‑term price mover. Board Chair Transition
• Neutral Sentiment: Pipeline diversification updates — Advances in lupus and SMA programs improve long‑term optionality but will take time to drive revenue; these were noted by coverage but are not immediate catalysts. Pipeline Advances
• Neutral Sentiment: Short‑interest data appears inconsistent — Recent feeds reporting a “significant increase” actually show zero shares, so no clear short‑squeeze dynamics are evident from the available data. (internal short‑interest entries)
• Negative Sentiment: Insider selling — Senior insider Priya Singhal sold 2,660 shares (~$531k), which some investors interpret as a modest negative signal about near‑term insider conviction. Insider Form 4
• Negative Sentiment: Legacy franchise pressure and execution risks — Analysts caution that MS franchise erosion and the challenges of scaling Leqembi access/commercialization could limit upside and add execution risk. Franchise Pressure Analysis

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.